/

NXTC

NextCure, Inc.Closed

6.28−0.36 −5.42%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delay

Open

6.58

Prev close

6.64

Day range

6.216.76

52-week range

1.5515.74

Volume

54.69K0.03×

Mkt cap

28.75M

P/E ttm

—

Fwd P/E

-1.07

EPS ttm

-8.71

Div yield

0.00%

Earnings

—

From 52w high

−60.10%

Price Chart

Yahoo Finance · delayed

NXTCOct 12, 2026O 7.08H 7.52L 6.03C 6.64−0.54 (−7.52%)Vol 130.40K

SMA 506.30
SMA 2008.37

1Y change −0.15% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

NXTC NextCure, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +31.49%
1 month: −5.14%
3 months: +204.59%
6 months: −46.10%
Year to date: −53.21%
1 year: −0.15%

Valuation & ownership

Market cap: 28.75M
Enterprise value: 13.32M
P/E (ttm): —
Forward P/E: -1.07
PEG ratio: —
Price / book: 2.10
Price / sales (ttm): —
EV / EBITDA: -0.36
EPS (ttm): -8.71
EPS (forward): -5.90
Beta (5y monthly): 1.35
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 4.58M
Float: 2.93M
Short % of float: 4.66%
Short ratio (days): 2.01
Held by insiders: 8.64%
Held by institutions: 52.75%
Avg volume (3m): 2.11M
50-day average: 6.30
200-day average: 8.37
52-week change: −0.15%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 57.0
vs 50-day SMA: +5.38%
vs 200-day SMA: −20.69%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 12.06%
Realised vol (20d, ann.): 111.9%
From 52-week high: −57.81%
From 52-week low: +328.39%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

20.00

+218.47% implied

Low 20.00Median 20.00High 20.00

Recommendation trend

Now1 / 0 / 0
1m ago3 / 0 / 0

Buy / hold / sell counts

DES

About NextCure, Inc.

Yahoo Finance profile

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.

Sector: Healthcare
Industry: Biotechnology
Employees: 40
Headquarters: Baltimore, MD, United States
Website: nextcure.com
Officers: Mr. Michael S. Richman MSBA Co-Founder, CEO, President & Director
Dr. Timothy Mayer Ph.D. Chief Operating Officer
Dr. Udayan Guha M.D., Ph.D. Chief Medical Officer
Dr. Lieping Chen M.D., Ph.D. Co-Founder & Chairman of Scientific Advisory Board

SEAS

Seasonality · NXTC

2019–2026 · monthly returns

Strongest month Oct +13.61%Weakest month Apr −14.36%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-23.5	17.2	-16.0	-13.8	-32.7	-74.2	159.1	54.2	-21.6	25.3			−55.7%
2025	4.4	-3.2	-38.4	-3.1	5.8	-6.5	-10.1	1.4	16.5	115.0	11.8	0.7	+53.4%
2024	7.0	41.8	28.9	-45.7	27.3	3.2	1.9	-9.3	-6.8	-3.3	-11.7	-34.1	−32.4%
2023	18.4	-7.2	-4.5	2.0	13.9	4.7	-4.4	-15.1	-11.6	-20.2	14.6	-3.4	−19.1%
2022	-7.2	-12.0	-0.8	-14.4	-6.2	20.5	-8.5	-4.7	-32.9	-9.1	-43.6	0.0	−76.5%
2021	6.3	-2.0	-11.9	-12.4	-10.5	2.3	-13.7	10.0	-11.5	22.0	-24.0	-4.0	−45.0%
2020	-24.1	-2.3	-11.2	-12.5	-3.7	-31.3	-58.4	0.8	-2.1	9.8	4.8	7.7	−80.6%
2019						-19.5	46.7	58.1	-11.2	-19.0	91.2	17.8	+202.5%

INSD

Insider Activity · NXTC

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

346.8K shares

Sells, 6 months

30K shares

Net shares

+316.8K

Net change in insider shares

+401.20%

Date	Insider	Transaction	Shares	Value
Aug 9, 2026	Simcere Zaiming, IncUnknown	Sale at price 6.16 per share.	30K	$184.80K
Jul 30, 2026	Adar1 Capital Management LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 4.14 - 5.00 per share.	329.2K	$1.60M
Jul 28, 2026	Adar1 Capital Management LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 4.95 - 5.00 per share.	17.6K	$87.71K

13F

Investors Holding NXTC

latest 13F filings of 29 followed managers

Investors holding NXTC
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$273.9K	0.00%	171.20K	+183%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

NXTC

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

NXTC

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About NextCure, Inc.

Seasonality · NXTC

Insider Activity · NXTC

Congress Trades · NXTC

Investors Holding NXTC

Investors Holding NXTC

Congress Trades · NXTC

Seasonality · NXTC

Insider Activity · NXTC

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About NextCure, Inc.

Financial Snapshot

Earnings & Dividends

News